The Priority Review

Clinical trials Brief

Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction

The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.

Primary source

ClinicalTrials.gov registry record, November 16, 2026

A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction

Read the source: A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation